CAMBRIDGE, Mass., July 24, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused…
CONSHOHOCKEN, Pa., July 24, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its…
Presentations will include an encore of the positive interim Phase 1/2 results presented in April at the 76th Annual American…
BOSTON and SAN DIEGO, July 24, 2024 (GLOBE NEWSWIRE) -- Beacon Biosignals, a leader in at-home sleep monitoring and computational…
Over 100,000 individuals lost their lives from overdoses last year, the majority of which were opioid related. While opioid overdoses…
Phase 2 dosing plan, agreed with FDA, paves the way to initiate patient enrollmentFOSTER CITY, Calif., July 24, 2024 (GLOBE…
NEW YORK, July 24, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology…
SOUTH SAN FRANCISCO, Calif., July 24, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural…
Skye introduces collaboration with Beacon Biosignals to evaluate potential impact of Nimacimab on sleep quality and sleep apneaSAN DIEGO, July…
Boston (July 24, 2024)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to…